Gout flare prophylaxis during management of chronic gout with febuxostat, a non-purine selective inhibitor of xanthine oxidase.

被引：0
作者：
Wortmann, R
Becker, MA
Schumacher, HR
MacDonald, P
Palo, WA
Joseph-Ridge, N
机构：
[1] Univ Oklahoma, Tulsa, OK USA
[2] Univ Chicago, Chicago, IL 60637 USA
[3] Univ Penn, VAMC, Philadelphia, PA 19104 USA
[4] TAP Pharmaceut Prod Inc, Lake Forest, IL USA
来源：
ARTHRITIS AND RHEUMATISM | 2004年 / 50卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S335 / S336
页数：2
相关论文
共 50 条
[41]   An Allopurinol-Controlled, Randomized, Double-Dummy, Double-Blind, Parallel Between-Group, Comparative Study of Febuxostat (TMX-67), a Non-Purine-Selective Inhibitor of Xanthine Oxidase, in Patients With Hyperuricemia Including Those With Gout in Japan [J].
Kamatani, Naoyuki ;
Fujimori, Shin ;
Hada, Toshikazu ;
Hosoya, Tatsuo ;
Kohri, Kenjiro ;
Nakamura, Toshitaka ;
Ueda, Takanori ;
Yamamoto, Tetsuya ;
Yamanaka, Hisashi ;
Matsuzawa, Yuji .
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2011, 17 (04) :S13-S18
[42]   A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout [J].
Tatsuo Hosoya ;
Kazuki Furuno ;
Shingo Kanda .
Clinical and Experimental Nephrology, 2020, 24 :71-79
[43]   A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout [J].
Hosoya, Tatsuo ;
Furuno, Kazuki ;
Kanda, Shingo .
CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2020, 24 (SUPPL 1) :71-79
[44]   Phase II, dose-response, safety and efficacy clinical trial of a new oral xanthine oxidase inhibitor TMX-67 (febuxostat) in subjects with gout. [J].
Joseph-Ridge, N .
ARTHRITIS AND RHEUMATISM, 2002, 46 (09) :S142-S142
[45]   Major Cardiovascular Events in Patients with Gout and Associated Cardiovascular Disease or Heart Failure and Chronic Kidney Disease Initiating a Xanthine Oxidase Inhibitor [J].
Foody, JoAnne ;
Turpin, Robin S. ;
Tidwell, Beni A. ;
Lawrence, Debra ;
Schulman, Kathy L. .
AMERICAN HEALTH AND DRUG BENEFITS, 2017, 10 (08) :393-400
[46]   Placebo-Controlled, Double-Blind Study of the Non-Purine-Selective Xanthine Oxidase Inhibitor Febuxostat (TMX-67) in Patients With Hyperuricemia Including Those With Gout in Japan; Phase 3 Clinical Study (vol 17, pg S19, 2011) [J].
Kamatani, Naoyuki ;
Fujimori, Shin ;
Hada, Toshikazu ;
Hosoya, Tatsuo ;
Kohri, Kenjiro ;
Nakamura, Toshitaka ;
Ueda, Takanori ;
Yamamoto, Tetsuya ;
Yamanaka, Hisashi ;
Matsuzawa, Yuji .
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2014, 20 (06) :E1-E1
[47]   Placebo-Controlled Double-Blind Dose-Response Study of the Non-Purine-Selective Xanthine Oxidase Inhibitor Febuxostat (TMX-67) in Patients With Hyperuricemia (Including Gout Patients) in Japan: Late Phase 2 Clinical Study (vol 17, pg S35, 2011) [J].
Kamatani, Naoyuki ;
Fujimori, Shin ;
Hada, Toshikazu ;
Hosoya, Tatsuo ;
Kohri, Kenjiro ;
Nakamura, Toshitaka ;
Ueda, Takanori ;
Yamamoto, Tetsuya ;
Yamanaka, Hisashi ;
Matsuzawa, Yuji .
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2014, 20 (06) :E2-E2
[48]   Excess Deaths Upon Cessation of Xanthine Oxidase Inhibitor Treatment-Data From the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial: Comment on the Article by Choi et al [J].
Bubb, Michael R. .
ARTHRITIS & RHEUMATOLOGY, 2019, 71 (08) :1391-1392
[49]   An Allopurinol-Controlled, Multicenter, Randomized, Open-Label, Parallel Between-Group, Comparative Study of Febuxostat (TMX-67), a Non-Purine-Selective Inhibitor of Xanthine Oxidase, in Patients With Hyperuricemia Including Those With Gout in Japan: Phase 2 Exploratory Clinical Study (vol 17, pg S44, 2011) [J].
Kamatani, Naoyuki ;
Fujimori, Shin ;
Hada, Toshikazu ;
Hosoya, Tatsuo ;
Kohri, Kenjiro ;
Nakamura, Toshitaka ;
Ueda, Takanori ;
Yamamoto, Tetsuya ;
Yamanaka, Hisashi ;
Matsuzawa, Yuji .
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2014, 20 (06) :E3-E3
[50]   A Repeated Oral Administration Study of Febuxostat (TMX-67), a Non-Purine-Selective Inhibitor of Xanthine Oxidase, in Patients With Impaired Renal Function in Japan: Pharmacokinetic and Pharmacodynamic Study (vol 17, pg S27, 2011) [J].
Hosoya, Tatsuo ;
Ohno, Iwao .
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2014, 20 (06) :E2-E2
12345